Guardant Health Inc (GH) Expected to Post Q3 2018 Earnings of ($0.28) Per Share

Guardant Health Inc (NASDAQ:GH) – Equities researchers at Leerink Swann issued their Q3 2018 earnings per share estimates for shares of Guardant Health in a research report issued on Monday, October 29th. Leerink Swann analyst P. Souda expects that the company will post earnings per share of ($0.28) for the quarter. Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Guardant Health’s Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($1.03) EPS, Q1 2019 earnings at ($0.30) EPS, Q2 2019 earnings at ($0.32) EPS, Q3 2019 earnings at ($0.33) EPS, Q4 2019 earnings at ($0.34) EPS, FY2019 earnings at ($1.29) EPS, FY2020 earnings at ($0.92) EPS and FY2021 earnings at ($0.50) EPS.

Several other analysts have also recently weighed in on GH. Cowen began coverage on shares of Guardant Health in a research note on Monday. They issued an “outperform” rating on the stock. William Blair began coverage on shares of Guardant Health in a research note on Monday. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. began coverage on shares of Guardant Health in a research note on Monday. They issued an “overweight” rating and a $42.00 price objective on the stock. Finally, Bank of America began coverage on shares of Guardant Health in a research note on Monday. They issued a “neutral” rating and a $37.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $39.50.



Shares of Guardant Health stock opened at $33.48 on Wednesday. Guardant Health has a twelve month low of $27.04 and a twelve month high of $44.25.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.

Read More: Diversification For Individual Investors

Earnings History and Estimates for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply